Bisphosphonate Treatment for Hypercalcemia in Oral Cancer Patients
Author Information
Author(s): Onizawa Kojiro, Yoshida Hiroshi
Primary Institution: University of Tsukuba, Japan
Hypothesis
The study investigates the efficacy of bisphosphonate treatment in patients with hypercalcemia associated with advanced oral cancer.
Conclusion
Bisphosphonate treatment can decrease serum calcium levels and may prolong survival slightly, but long-term survival remains poor in oral cancer patients with hypercalcemia.
Supporting Evidence
- The first administration of bisphosphonate effectively decreased serum calcium levels.
- Patients treated with bisphosphonate survived significantly longer than untreated patients.
- Repeated bisphosphonate administrations were less effective in controlling calcium levels.
Takeaway
This study looked at how a medicine called bisphosphonate helps people with high calcium levels due to mouth cancer. It found that while it can help a little, most people still don't live long after getting sick.
Methodology
A retrospective analysis of 16 hypercalcemic patients with advanced oral cancer, comparing those treated with bisphosphonate to those who were not.
Potential Biases
Potential bias due to non-randomized treatment assignment and small sample size.
Limitations
The study is retrospective and not randomized, which may introduce bias.
Participant Demographics
10 men and 6 women, aged 24 to 84 years, with a mean age of 60.4 years.
Statistical Information
P-Value
0.0050
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website